Home    Back

Op-724    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
93Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]1

93. Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]    [ 230 clinical trials,   215 drugs,   (DrugBank: 51 drugs),   34 drug target genes,   107 drug target pathways]
Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 230 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04047160
(ClinicalTrials.gov)		August 29, 201930/7/2019Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)An Open-Label, Dose-Finding Study for the CBP / ß-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)Primary Biliary Cholangitis (PBC);Liver Cirrhosis, BiliaryDrug: OP-724Kiminori Kimura, MDOHARA Pharmaceutical Co., Ltd.;Japan Agency for Medical Research and DevelopmentRecruiting20 Years74 YearsAll12Phase 1Japan